55
Views
4
CrossRef citations to date
0
Altmetric
Review

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

, , , , , , & show all
Pages 107-116 | Published online: 27 Mar 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Mathias Woschek, Niels Kneip, Katrin Jurida, Ingo Marzi & Borna Relja. (2016) Simvastatin Reduces Cancerogenic Potential of Renal Cancer Cells via Geranylgeranyl Pyrophosphate and Mevalonate Pathway. Nutrition and Cancer 68:3, pages 420-427.
Read now
Yousef Zakharia, Kais Zakharia & Olivier Rixe. (2015) Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. Expert Opinion on Drug Discovery 10:8, pages 925-935.
Read now
Giuseppe Bronte, Enrico Bronte, Giuseppina Novo, Gianfranco Pernice, Francesca Lo Vullo, Emmanuela Musso, Fabrizio Bronte, Eliana Gulotta, Sergio Rizzo, Christian Rolfo, Nicola Silvestris, Viviana Bazan, Salvatore Novo & Antonio Russo. (2015) Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opinion on Drug Safety 14:2, pages 253-267.
Read now

Articles from other publishers (1)

Ying Chen, Akiyuki Suzuki, Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama & Yazdi K. Pithavala. (2015) Axitinib plasma pharmacokinetics and ethnic differences. Investigational New Drugs 33:2, pages 521-532.
Crossref